Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bapotulimab · 1 trial · 2 indications
Maximum plasma concentration after single dose
Area under the plasma concentration curve after single dose
| Arm | Type | Description |
|---|---|---|
| Dose escalation_Monotherapy | EXPERIMENTAL | Patients with solid tumor types considered immunosensitive |
| Dose escalation_Combination therapy | EXPERIMENTAL | Patients with solid tumor types considered immunosensitive |
| Expansion HNSCC_Combination therapy | EXPERIMENTAL | Patients with head and neck squamous cell carcinoma (HNSCC) |
| Name | Type | Description |
|---|---|---|
| Bapotulimab (BAY1905254) | DRUG | Intravenous administration of escalating doses of Bapotulimab |
| Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®) | DRUG | Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab |
Main Inclusion Criteria: * Male or female patients aged ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Patients must have measurable disease (at least one unidimensional measurable lesion by Computed tomography \[CT\] or Magnetic resonance imaging \[MRI\]) p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Bapotulimab is an investigational small molecule being studied for the treatment of advanced solid tumors, including head and neck squamous cell carcinoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Bapotulimab is being developed by Bayer AG, a pharmaceutical company traded on the stock exchange under the ticker symbol BAYRY. The drug is currently in Phase 1 clinical trials for oncology indications.
Bapotulimab is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies and is still being evaluated in clinical trials for safety and efficacy in patients with advanced solid tumors.
Bapotulimab has been studied in one clinical trial, identified as NCT03666273. This was a Phase 1 study that evaluated the drug in combination with pembrolizumab in patients with head and neck cancer that had returned or metastasized and expressed PD-L1. The trial has been completed.
Yes, Bapotulimab is also known as BAY1905254. In clinical trial NCT03666273, the drug is referred to by this alternative name, and the study title explicitly mentions both names to identify the investigational agent being evaluated.